Clinical trials
Phase 3 Atrial Fibrillation trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
98 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 6 |
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 7 |
| 2007 | 9 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 9 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 63 |
| Terminated | 16 |
| Recruiting | 11 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sanofi | 9 |
| Texas Cardiac Arrhythmia Research Foundation | 7 |
| Astellas Pharma Inc | 3 |
| Biosense Webster, Inc. | 3 |
| Boehringer Ingelheim | 3 |
| Boston Scientific Corporation | 3 |
| Daiichi Sankyo | 3 |
| Mayo Clinic | 3 |
| Solvay Pharmaceuticals | 3 |
| AtriCure, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atrial Fibrillation | 98 |
| Stroke | 15 |
| Atrial Flutter | 12 |
| Arrhythmias, Cardiac | 9 |
| Heart Failure | 4 |
| Thrombosis | 4 |
| Cardiovascular Diseases | 3 |
| Embolism | 3 |
| Heart Diseases | 3 |
| Hemorrhage | 3 |
Trials
Showing 1 to 25 of 98. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.